Seeking Alpha

Hugan tablet sales temporarily halted

  • The China Food and Drug Administration halts the sale of Tianyin Pharmaceuticals' (TPI +3.1%) liver drug Hugan as it performs due diligence on its price and GMP before awarding the firm the right to sell the product in Zhejiang province. The agency's action is a customary part of its regulatory process.
  • The product contributes ~$600K in annual sales.
  • The company expects the examination to be over in April and sales will recommence.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|